<DOC>
	<DOC>NCT00511342</DOC>
	<brief_summary>The primary purpose of this study is to evaluate the effects of the NOMAC-E2 combined oral contraceptive (COC) on bone mineral density (BMD).</brief_summary>
	<brief_title>Effects on Bone Mineral Density (BMD) of the Combined Oral Contraceptive NOMAC-E2 Compared to a COC Containing LNG/EE (292005)(P05765)(COMPLETED)</brief_title>
	<detailed_description />
	<mesh_term>Ethinyl Estradiol</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Contraceptives, Oral</mesh_term>
	<mesh_term>Levonorgestrel</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<mesh_term>Contraceptives, Oral, Combined</mesh_term>
	<criteria>Inclusion criteria: Sexually active women, at risk for pregnancy and not planning to use condoms during treatment; At least 20 but not older than 35 years of age at the time of screening; BMI = 17 and = 35; Good physical and mental health; Willing to give informed consent in writing; Willing to take part in the trial for two years. Exclusion criteria: Family history of osteoporotic fracture below the age of 70; Postgastrectomy; History of eating disorder, viz. anorexia nervosa, bulimia; Endocrine disorder (including controlled diabetes, [para]thyroid disease, Cushing's disease); Rheumatoid arthritis; Significant scoliosis; Fasting parathyroid hormone (PTH) outside the reference range at screening; Fasting calcitonin outside the reference range at screening; Prolactin above the reference range (hyperprolactinemia) at screening; Fasting cholesterol and/or triglycerides above the reference range for age at screening (treatment with lipid lowering drugs not allowed); Engaging in vigorous exercise such as marathon, competitive swimming, triathlon; Smoking more than ten cigarettes/day; Use of more than two units of alcohol a day; Use of one or more of the following drugs: gonadotropin releasing hormone (GnRH) analogues (also past use for more than six months at any time, or for any period of time less than six months ago is a contraindication); systemic or inhaled administration of corticosteroids (also past use for more than one year, less than five years ago or any period of time in the past year is a contraindication); thiazide diuretics; thyroid hormone; bisphosphonates; calcium supplementation in combination with vitamin D supplementation/ calcitonin; ever treatment after childhood with fluorides; Contraindications for contraceptive steroids An abnormal cervical smear (i.e.: dysplasia, cervical intraepithelial neoplasia[CIN], squamous intraepithelial lesion [SIL], carcinoma in situ, invasive carcinoma) at screening; Clinically relevant abnormal laboratory result at screening as judged by the investigator; Use of an injectable hormonal method of contraception; within 6 months of an injection with a 3month duration, within 4 months of an injection with a 2month duration, within 2 months of an injection with a 1month duration; Within 12 months after a pregnancy prior to the start of trial medication; Breastfeeding or within 12 months after stopping breastfeeding prior to the start of trial medication; Present use or use within 2 months prior to the start of the trial medication of the following drugs: phenytoin, barbiturates, primidone, carbamazepine, oxcarbazepine, topiramate, felbamate, rifampicin, nelfinavir, ritonavir, griseofulvin, ketoconazole, sex steroids (other than pre and posttreatment contraceptive method) and herbal remedies containing Hypericum perforatum (St John's Wort); Administration of investigational drugs and/or participation in another clinical trial within 2 months prior to the start of the trial medication or during the trial period.</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>